Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkins lymphoma in European and Australian clinical practice
A partir de données européennes et australiennes, cette étude analyse les coûts d'une neutropénie fébrile induite par la chimiothérapie chez des patients atteints d'un lymphome non hodgkinien
BACKGROUND:Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown.METHODS:Data were obtained from a European (97%) and Australian (3%) observational study of patients with non-Hodgkin's lymphoma (NHL) receiving CHOP ([PLUS-MINUS SIGN]rituximab) chemotherapy. For each patient, each cycle of chemotherapy within the course, and each occurrence of FN within cycles, was identified. Patients developing FN in a given cycle ("FN patients"), starting with the first, were matched to those who did not develop FN in that cycle ("comparison patients"), irrespective of subsequent FN events. FN-related healthcare costs ([POUND SIGN]2010) were tallied for the initial FN event as well as follow-on care and FN events in subsequent cycles.RESULTS:Mean total cost was [POUND SIGN]5776 (95%CI [POUND SIGN]4928-[POUND SIGN]6713) higher for FN patients (n = 295) versus comparison patients, comprising [POUND SIGN]4051 ([POUND SIGN]3633-[POUND SIGN]4485) for the initial event and a difference of [POUND SIGN]1725 ([POUND SIGN]978-[POUND SIGN]2498) in subsequent cycles. Among FN patients requiring inpatient care (76% of all FN patients), mean total cost was higher by [POUND SIGN]7259 ([POUND SIGN]6327-[POUND SIGN]8205), comprising [POUND SIGN]5281 ([POUND SIGN]4810-[POUND SIGN]5774) for the initial hospitalization and a difference of [POUND SIGN]1978 ([POUND SIGN]1262-[POUND SIGN]2801) in subsequent cycles.CONCLUSIONS:Cost of chemotherapy-induced FN among NHL patients in European and Australian clinical practice is substantial; a sizable percentage is attributable to follow-on care and subsequent FN events.
BMC Cancer 2012